Researchers continue to excited about the medication , a groundbreaking dual compound showing significant results in early trials for body loss . It acts by targeting both pathways : GLP-1 and GIP, which , when stimulated, support influence appetite and improve energy expenditure . Early reports demonstrate substantial size loss and possible advant